Scarica l'app Stockscreener
4.13
4.29%
0.17
Dopo l'orario di chiusura:
4.13
Precedente Chiudi:
$3.96
Aprire:
$3.93
Volume 24 ore:
5.31M
Relative Volume:
1.07
Capitalizzazione di mercato:
$827.39M
Reddito:
$314.00K
Utile/perdita netta:
$-40.23M
Rapporto P/E:
-14.75
EPS:
-0.28
Flusso di cassa netto:
$-84.71M
1 W Prestazione:
-0.24%
1M Prestazione:
+57.63%
6M Prestazione:
+61.96%
1 anno Prestazione:
+233.06%
Intervallo 1D:
$3.88
$4.19
Intervallo di 1 settimana:
$3.78
$4.30
Portata 52W:
$1.03
$4.40
Atai Life Sciences N V Stock (ATAI) Company Profile
Nome
Atai Life Sciences N V
Settore
Industria
Telefono
49 89 2153 9035
Indirizzo
WALLSTRASSE 16, BERLIN
Confronta ATAI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
4.13 | 840.09M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Iniziato | Oppenheimer | Outperform |
| 2024-11-18 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-03 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2021-11-30 | Iniziato | Maxim Group | Buy |
| 2021-11-11 | Iniziato | ROTH Capital | Buy |
| 2021-10-18 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-01 | Iniziato | Jefferies | Buy |
| 2021-07-13 | Iniziato | Berenberg | Buy |
| 2021-07-13 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-13 | Iniziato | Cantor Fitzgerald | Buy |
| 2021-07-13 | Iniziato | Citigroup | Buy |
| 2021-07-13 | Iniziato | Cowen | Outperform |
| 2021-07-13 | Iniziato | Credit Suisse | Outperform |
| 2021-07-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
Atai Life Sciences N.V. Bounces Off Moving Average SupportConservative Long Term Growth Plans Under Review - metal.it
Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT - Insider Monkey
How volatile is Atai Life Sciences N.V. stock compared to the marketAchieve consistent profits with expert advice - Jammu Links News
Atai Life Sciences N.V. Stock Analysis and ForecastFree Stock Market Return Analysis - Jammu Links News
What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 monthsBoost your returns with professional guidance - Jammu Links News
How many analysts rate Atai Life Sciences N.V. as a “Buy”Dynamic profit expansion - Jammu Links News
What are the latest earnings results for Atai Life Sciences N.V.Maximize your gains with professional insights - Jammu Links News
What drives Atai Life Sciences N.V. stock priceGet timely advice on market trends - Jammu Links News
Does Atai Life Sciences N.V. stock perform well during market downturnsTrack top-performing stocks effortlessly - Jammu Links News
How does Atai Life Sciences N.V. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News
What is the risk reward ratio of investing in Atai Life Sciences N.V. stockDiscover breakthrough stocks with expert help - jammulinksnews.com
How does Atai Life Sciences N.V. compare to its industry peersSky-high return potential - Jammu Links News
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Insider Monkey
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg.com
H.C. Wainwright raises atai Life Sciences stock price target to $15 on BPL-003 potential - Investing.com Nigeria
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Published on: 2025-07-30 03:07:04 - metal.it
What makes Atai Life Sciences N.V. stock price move sharplySwing Setup With Technical Confirmation Explained - metal.it
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - 富途牛牛
How did ATAI's revenue and expenses shift in Q4 2024? - AInvest
Oppenheimer initiates coverage on ATAI Life Sciences with Outperform rating, $14 PT. - AInvest
Oppenheimer initiates atai Life Sciences stock with Outperform rating By Investing.com - Investing.com Nigeria
Oppenheimer initiates atai Life Sciences stock with Outperform rating - Investing.com
Published on: 2025-07-29 09:29:36 - metal.it
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha
ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade
Why Is ATAI Life Sciences Stock Trading Lower On Monday? - inkl
Published on: 2025-07-28 17:17:36 - beatles.ru
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - 富途牛牛
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday - Benzinga
What is Atai Life Sciences N.V. company’s growth strategyGet insider insights into market trends - Jammu Links News
What are Atai Life Sciences N.V. company’s key revenue driversExceptional stock performance - Jammu Links News
Why Atai Life Sciences N.V. stock attracts strong analyst attentionFree Access to Community - metal.it
Atai Life Sciences (ATAI) Shares Drop 12% After Schizophrenia Dr - GuruFocus
Atai Life Sciences shares fall 14.29% after-hours as schizophrenia drug fails to meet main endpoint. - AInvest
Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha
Published on: 2025-07-26 00:30:53 - PrintWeekIndia
ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com UK
Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan
Canaccord Increases Atai Life Sciences (ATAI) PT, Keeps Buy Rating - Insider Monkey
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is Atai Life Sciences N.V. a good long term investmentBreakout profit opportunities - PrintWeekIndia
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
What analysts say about Atai Life Sciences N.V. stockMassive wealth growth - Autocar Professional
Atai Life Sciences N V Azioni (ATAI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):